Glaukos GKOS Glaucoma — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Glaukos in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Glaukos's glaucoma — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Glaukos's glaucoma — revenue?
- Glaukos (GKOS) reported glaucoma — revenue of $129.26M in Q1 2026.
- How has Glaukos's glaucoma — revenue changed year-over-year?
- Glaukos's glaucoma — revenue increased by 46.7% year-over-year, from $88.14M to $129.26M.
- What is the long-term trend for Glaukos's glaucoma — revenue?
- Over 4 years (2021 to 2025), Glaukos's glaucoma — revenue has grown at a 16.1% compound annual growth rate (CAGR), from $231.98M to $421.07M.
- What does glaucoma — revenue mean?
- The total net revenue earned from the sale of glaucoma-related medical devices and products.
- How do you interpret glaucoma — revenue?
- An increase indicates successful market penetration, higher procedure volumes, or effective commercial execution within the glaucoma treatment space. A decrease may signal increased competition, pricing pressure, or a decline in the adoption of the company's surgical technologies.
- How does glaucoma — revenue compare across companies?
- Comparable to segment-specific net revenue metrics reported by other medical device companies specializing in ophthalmology or surgical implants.